EuroPCR 2024 | DOCTORS-LM Trial: CTO Optimizes Stent Outcomes in Left Main Disease?

The aim of this randomized open study was to determine whether CTO guided left main percutaneous coronary intervention (PCI) is superior to fluoroscopy guided PCI, using fractional flow reserve (FFR) after stenting.

EuroPCR 2024

The secondary outcomes were procedural success (successful implantation, malposition, edge dissection or stent collapse) and major adverse cardiovascular events (MACE) at one year.

The study included 197 non-ST elevation acute coronary syndrome (NST ACS) patients with unstable angina, stable angina or silent ischemia, with significant angiographic or FFR left main lesion (%DS ≥50% and ≤0.80 respectively)and ≤ 22 Syntax score.

CTO patients were assessed prior and post PCI, while the angiography only patients received fluoroscopy. Both groups had a final assessment and FFR was carried out after 12 months. 

As to the primary FFR outcomes, there were no significant differences between the groups (0.894 ± 0.049 vs 0.889 ± 0.056; P=0.5237). However, when looking at procedural success, a significant difference was observed in favor of CTO (58.9% vs 34.4%; P=0.0009), especially as regards sub-expansion optimization (P=0.08), malposition (P=0.0005) and stent collapse (P=0.0045). The difference in MACE was smaller and with no statistical significance mainly due to target vessel failure (TVF).

Read also: EuroPCR 2024 | Prognostic Value of MRR in STEMI: Group Analysis of Individual Patients.

Therefore, the authors concluded that, compared against conventional PCI, the use of CTO did not show significant differences in functional outcomes (FFR). However, it did show better procedural success and lower incidence of new revascularization. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Reference: Presented by Nicolas Meneveau at Late-Breaking Clinical Trials, EuroPCR 2024, May 14-17, Paris, France.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...